Optimized formulation of tobramycin for aerosolization

Details Optimized formulation of tobramycin for aerosolization Optimized formulation of tobramycin for aerosolization

2006-01-17

2006-01-17

Warren, James Q. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S036000, C514S035000, C514S025000, C536S004100

Reexamination Certificate

active

06987094

ABSTRACT:
The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacteriumPseudomonas aeruginosaassociated to lung diseases such as cystic fibrosis.

REFERENCES:
patent: 5508269 (1996-04-01), Smith et al.
patent: 734249 (1996-10-01), None
patent: WO 96/12471 (1996-05-01), None
patent: 96 12471 (1996-05-01), None
Le Brun PPH et al., “Inhalation of tobramycin in cystic fibrosis Part 2: Optimization of the tobramycin solution for a jet and an ultrasonic nebulizer.” International Journal of Pharmaceutics, vol. 189, No. 2, Nov. 5, 1999, pp. 215-225.
Brandl M and GU L:“Degradation of tobramycin in aqueous solution” Drug Development and Industrial Pharmacy, vol. 18, no 13, 1992, pp. 1423-1436.
Nikolaizik et al, Eur. J. Pediatr, (1996)155: pp. 608-611.
McCallion et al, International Journal of Pharmaceutics (1996) 130, pp. 1-11.
Mann et al, British Medical Journal, Aug. 25, 1984, vol. 289, p. 469.
Newman et al, Thorax, 1988, 43, pp. 318-322.
Smaidone et al, Journal of Aerosol Medicine, vol. 1, No. 2 (1988) pp. 113-126.
Thomas et al, Eur. Respir. J., (1991) vol. 4, pp. 616-622.
Wall et al, The Lancet, 1983, Jun. 11, 1983, p. 1325.
Ramsey et al, The New England Journal of Medicine, Jun. 17, 1993, vol. 328, No. 24, pp. 1740-1746.
The Lancet, Jul. 23, 1988, vol. 11, p. 202.
La Brun et al, International Journal of Pharmaceutics, Apr. 27, 1999, vol. 189, pp. 205-214.
Derbracher et al, Aternwegs und Lung, 1994, 20, pp. 381-382.

Affiliated with

Also associated with

Rating

Optimized formulation of tobramycin for aerosolization does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Optimized formulation of tobramycin for aerosolization, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Optimized formulation of tobramycin for aerosolization will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3578401